MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines
Authors
Keywords
MicroRNAs, Breast cancer, Cell cycle and cell division, Drug screening, Signal inhibition, Transcription factors, Biomarkers, Signal initiation
Journal
PLoS One
Volume 14, Issue 5, Pages e0216400
Publisher
Public Library of Science (PLoS)
Online
2019-05-08
DOI
10.1371/journal.pone.0216400
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Resistance to proteasome inhibitors and other targeted therapies in myeloma
- (2018) Craig T. Wallington-Beddoe et al. BRITISH JOURNAL OF HAEMATOLOGY
- Primate-specific miRNA-637 inhibited tumorigenesis in human pancreatic ductal adenocarcinoma cells by suppressing Akt1 expression
- (2018) Rui-lian Xu et al. EXPERIMENTAL CELL RESEARCH
- Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma
- (2018) Mariah L. Farrell et al. Frontiers in Endocrinology
- PARP inhibitors: Clinical utility and possibilities of overcoming resistance
- (2017) Benjamin G. Bitler et al. GYNECOLOGIC ONCOLOGY
- The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis
- (2017) Yingchun Liang et al. Cell Death & Disease
- MicroRNA regulation of progesterone receptor in breast cancer
- (2017) Avital Gilam et al. Oncotarget
- TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition
- (2016) Prahlad V. Raninga et al. CELL CYCLE
- MicroRNAs and cancer resistance: A new molecular plot
- (2016) F Fanini et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- An overview of microRNAs
- (2015) Scott M. Hammond ADVANCED DRUG DELIVERY REVIEWS
- Understanding drugs in breast cancer through drug sensitivity screening
- (2015) Katharina Uhr et al. SpringerPlus
- Let-7 miRNAs Modulate the Activation of NF-κB by Targeting TNFAIP3 and Are Involved in the Pathogenesis of Lupus Nephritis
- (2015) Jun Liu et al. PLoS One
- Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review
- (2014) Vincent A. de Weger et al. ANTI-CANCER DRUGS
- Identification and consequences of miRNA–target interactions — beyond repression of gene expression
- (2014) Jean Hausser et al. NATURE REVIEWS GENETICS
- MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis
- (2013) W Wu et al. BRITISH JOURNAL OF CANCER
- Identification of miRNA modulators to PARP inhibitor response
- (2013) Sari Neijenhuis et al. DNA REPAIR
- Epigenetics and ncRNAs in Brain Function and Disease: Mechanisms and Prospects for Therapy
- (2013) Miguel A. Varela et al. Neurotherapeutics
- Stat3-coordinated Lin-28–let-7–HMGA2 and miR-200–ZEB1 circuits initiate and maintain oncostatin M-driven epithelial–mesenchymal transition
- (2013) L Guo et al. ONCOGENE
- MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
- (2012) Marilena V. Iorio et al. EMBO Molecular Medicine
- Estrogen and retinoic acid antagonistically regulate several microRNA genes to control aerobic glycolysis in breast cancer cells
- (2012) Anne Saumet et al. Molecular BioSystems
- PARP inhibitors – current status and the walk towards early breast cancer
- (2011) Jennifer Glendenning et al. BREAST
- Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling
- (2011) Jin-fang Zhang et al. HEPATOLOGY
- MicroRNAs in body fluids—the mix of hormones and biomarkers
- (2011) Maria Angelica Cortez et al. Nature Reviews Clinical Oncology
- Gene silencing by microRNAs: contributions of translational repression and mRNA decay
- (2011) Eric Huntzinger et al. NATURE REVIEWS GENETICS
- MicroRNAs in the Pathogenesis of Cancer
- (2011) Francesca Lovat et al. SEMINARS IN ONCOLOGY
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- Histone Deacetylase Inhibitors Activate NF-κB in Human Leukemia Cells through an ATM/NEMO-related Pathway
- (2010) Roberto R. Rosato et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Estradiol Suppresses NF- B Activation through Coordinated Regulation of let-7a and miR-125b in Primary Human Macrophages
- (2010) A. J. Murphy et al. JOURNAL OF IMMUNOLOGY
- ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
- (2010) N. Munshi et al. MOLECULAR CANCER THERAPEUTICS
- miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
- (2010) Patryk Moskwa et al. MOLECULAR CELL
- Mammalian microRNAs predominantly act to decrease target mRNA levels
- (2010) Huili Guo et al. NATURE
- The widespread regulation of microRNA biogenesis, function and decay
- (2010) Jacek Krol et al. NATURE REVIEWS GENETICS
- Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
- (2010) Fiona M. Blows et al. PLOS MEDICINE
- Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines
- (2009) Antoinette Hollestelle et al. BREAST CANCER RESEARCH AND TREATMENT
- MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response
- (2009) Joris Pothof et al. EMBO JOURNAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started